Cardiometabolic & kidneyRandomised controlled trial
Telemedicine-supported lifestyle intervention for glycemic control in patients with coronary heart disease (CHD) and T2DM: multicenter, randomized controlled trial
- Randomised controlled trial
- multicentre
Authors' conclusion
In conclusion, a home-based lifestyle intervention with telemedicine support showed modest effects in patients with CHD and T2DM.
Study context
- Population
- Patients with combined CHD and T2DM (68 ± 8 years; 84% men)
- Participants
- 502 patients
- Comparison
- Home-based telemedicine-supported lifestyle intervention vs usual care
- Primary endpoint
- Glycated hemoglobin
- Follow-up
- 6 months
Primary result
As reported in the abstract
Mean between-group difference
−0.13 %
95% CI −0.25 to −0.01
P = 0.04
Lifestyle intervention vs Usual care
mean between-group difference −0.13 % (95% CI −0.25 to −0.01); P = 0.04
Further findings
events
| Outcome | Lifestyle intervention | Usual care |
|---|---|---|
| Deaths | 2 | 3 |
- Deaths — Deaths related to the intervention
- 0
Between-group differences after feedback and health literacy training discontinued · 12 months
- No statistically significant between-group differences
Safety
MACE · 12 months
P = 0.15
- MACE — Total MACE
- 31 patients (6.2%)
- MACE: main reason hospitalization for angina or revascularization (15 vs 8)
Hospitalizations potentially related to the intervention
- Events (HF decompensation, vertebral disc prolapse, inguinal hernia)
- 3
Original publication
Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial. Nat Med. Published 7 February 2025. doi:10.1038/s41591-025-03498-w
Summarised from the published abstract; every number is checked against it